Want to see SE:ASKER full AI Analyst Report?
ASKER Stock Chart & Stats
kr82.25
--
Market closed
kr82.25
--
Day’s Range― - ―
52-Week Rangekr56.20 - kr95.56
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.12M
Market Cap
kr26.46B
Enterprise Valuekr35.90B
Total Cash (Recent Filing)kr777.00M
Total Debt (Recent Filing)kr6.48B
Price to Earnings (P/E)38.7
Beta0.75
Next Earnings
Nov 04, 2026EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)1.78
Shares Outstanding383,706,480
10 Day Avg. Volume768,033
30 Day Avg. Volume1,116,507
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)4.74
Price to Sales (P/S)1.85
P/FCF Ratio42.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.81
Revenue Forecast (FY)kr19.15B
Bulls Say, Bears Say
Bulls Say
Improving Revenue And ProfitabilityRevenue growth combined with a substantial improvement in net margin indicates better earnings conversion and operating execution. If maintained, this creates greater capacity to reinvest in the healthcare distribution platform, support customers, and build earnings power over the next several quarters.
Stronger Capital StructureThe sharp reduction in leverage and growth in equity provide a more resilient financial foundation than in prior years. A stronger balance sheet can improve funding flexibility, reduce dependence on debt, and help the company pursue operational investment while absorbing normal business volatility.
Positive Cash GenerationPositive free cash flow that represents a meaningful share of earnings supports the quality of reported profits. This gives Asker internally generated resources for reinvestment, debt management, or other capital priorities, strengthening the durability of its business model over the medium term.
Bears Say
Modest Profitability BufferAlthough profitability has improved, relatively modest operating and net margins leave limited room to absorb adverse changes in pricing, costs, or operating efficiency. This can make earnings less resilient and requires continued execution to preserve improved profitability as the business expands.
Weakening Free-cash-flow MomentumThe recent decline in free cash flow and modest operating-cash-flow conversion could constrain financial flexibility if reinvestment or working-capital needs increase. Sustained cash-flow softness would make it harder to fund growth and reduce debt internally, even while accounting earnings remain positive.
Debt Remains Sizable With Moderate ReturnsLeverage has improved, but the absolute debt burden remains substantial and shareholder returns are only moderate. This combination means Asker still needs consistent execution to translate its larger asset base into stronger returns, while debt continues to represent a meaningful financial obligation.
Asker Healthcare Group AB News
ASKER FAQ
What was Asker Healthcare Group AB’s price range in the past 12 months?
Asker Healthcare Group AB lowest stock price was kr56.20 and its highest was kr95.56 in the past 12 months.
What is Asker Healthcare Group AB’s market cap?
Asker Healthcare Group AB’s market cap is kr26.46B.
When is Asker Healthcare Group AB’s upcoming earnings report date?
Asker Healthcare Group AB’s upcoming earnings report date is Nov 04, 2026 which is in 24 days.
How were Asker Healthcare Group AB’s earnings last quarter?
Asker Healthcare Group AB released its earnings results on Jul 21, 2026. The company reported kr0.57 earnings per share for the quarter, missing the consensus estimate of kr0.66 by -kr0.09.
Is Asker Healthcare Group AB overvalued?
According to Wall Street analysts Asker Healthcare Group AB’s price is currently Overvalued.
Does Asker Healthcare Group AB pay dividends?
Asker Healthcare Group AB pays a Notavailable dividend of kr0.39 which represents an annual dividend yield of 0.57%. See more information on Asker Healthcare Group AB dividends here
What is Asker Healthcare Group AB’s EPS estimate?
Asker Healthcare Group AB’s EPS estimate is 0.59.
How many shares outstanding does Asker Healthcare Group AB have?
Asker Healthcare Group AB has 383,706,480 shares outstanding.
What happened to Asker Healthcare Group AB’s price movement after its last earnings report?
Asker Healthcare Group AB reported an EPS of kr0.57 in its last earnings report, missing expectations of kr0.66. Following the earnings report the stock price went down -7.706%.
Which hedge fund is a major shareholder of Asker Healthcare Group AB?
Currently, no hedge funds are holding shares in SE:ASKER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Asker Healthcare Group AB
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion supplies, and wound dressings, alongside advanced medical apparatus like endoscopy systems, incubators, and ventilators. They also distribute pharmaceuticals and offer diagnostic instruments for conditions including diabetes and hypertension. The company equips operating rooms, polyclinics, and day surgery facilities with specialized medical devices, and provides veterinary equipment, hygiene solutions, and targeted products for urology, ultrasound diagnostics, laser treatment, and regenerative medicine. Additionally, their offerings include defibrillators, advanced wound care products, and critical protection and trauma supplies for emergency services, law enforcement, and military personnel, as well as products for beauty clinics. Beyond their core product range, Asker Healthcare Group develops and markets proprietary disposable medical items under the Evercare, Selefa, and Embra brands, and serves as a key distributor of ophthalmic surgical products. They also create and sell innovative solutions for time management, communication, and cognitive support, aimed at schools, assistive technology centers, and various public services. The group extends its offerings to a variety of patient support services, including specialized assistance for wound, diabetes, and urological care, in addition to ostomy, urology, and rehabilitation programs. They supply products for physiotherapy practices, provide exercise and treatment equipment, and offer both sales and rentals of mobility aids and rehabilitation devices, including pressure-relieving mattresses and cushions, which they also manufacture and distribute. Ambulance services are another facet of their diverse operations. Founded in 2018 and headquartered in Danderyd, Sweden, Asker Healthcare Group AB maintains an extensive operational presence across numerous European countries, specifically Sweden, Norway, Finland, Estonia, Latvia, Lithuania, the Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, the Czech Republic, and Poland.







